Acadia Healthcare Stock Tanks 22% as Major Fund Exits
💡 Key Takeaway
A major fund's complete exit from ACHC signals deep concerns over the company's financial health and turnaround prospects.
The $13 Million Exit
On February 17, 2026, investment firm Canyon Capital Advisors filed with the SEC to report it had sold its entire position in Acadia Healthcare Company (ACHC). The sale involved 521,774 shares, representing a stake valued at approximately $12.92 million at the end of the previous quarter.
This move comes during a difficult period for the behavioral healthcare provider. ACHC's stock price was $22.74 as of the report, reflecting a steep 22% decline over the past year. This performance starkly contrasts with the S&P 500, which gained about 16% over the same period.
The company itself reported mixed results. While revenue grew 5% for the year to $3.31 billion, its profitability was hit hard. The quarter included a massive $996.2 million goodwill impairment charge related to facility closures and write-downs.
Despite adding over 1,000 licensed beds in 2025, the company's adjusted EBITDA fell for the year, indicating that growth is coming at a higher cost and lower margin.
What This Means for Me
A Vote of No Confidence
Canyon Capital's decision to completely exit its position is a significant red flag for other investors. This isn't a routine portfolio rebalancing; it's a full divestment from a company that has been underperforming. Such a move by a major fund suggests a fundamental loss of confidence in ACHC's near-term recovery story.
The underlying financials justify this concern. The $996 million impairment charge is not just a paper loss; it indicates that past acquisitions or expansions are not delivering the expected value. This raises questions about the company's strategic decisions and capital allocation.
Furthermore, ACHC's net leverage ratio sits at 4.0x adjusted EBITDA. This is a high level of debt that leaves the company with little room for error. Any further operational missteps or economic downturns could put significant strain on its finances.
For investors, the key takeaway is that ACHC's problems run deeper than a temporary stock slump. The combination of declining profitability, high leverage, and a major investor exit points to structural challenges that may take considerable time to resolve.
Stock to Watch
| Stocks | Impact | Analysis | |
|---|---|---|---|
| ACHC | Negative | The primary stock affected, facing a major fund exit, declining profitability, and high financial leverage, signaling severe investor skepticism. |
Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
Investors should avoid ACHC until there are clear signs of operational stabilization and debt reduction.
The complete exit by a significant fund is a powerful bearish signal that outweighs the company's modest revenue growth. The high leverage and impairment charges create too much risk for most investors in the current environment.
What This Means for Me
Read More
DHR Q3 Earnings Beat: Biotechnology Strength Drives Growth
Bullish Danaher's Q3 earnings beat on strong biotechnology performance, with EPS growth of 11.6% and raised guidance, signaling robust demand and operational efficiency.
DHRACHCAGIOBDXOct 21, 2026Sea Limited's 20% Plunge: A Buying Opportunity or a Warning?
Bullish Sea Limited's recent sell-off on strategic moves (Monee spinoff and AI cloud entry) may be overdone, presenting a long-term buying opportunity as these initiatives could unlock significant value.
SENVDACRWVSPCXOct 23, 2026TTM Technologies Stock Plunges 21% on Supply Chain Bottlenecks
Bearish TTM Technologies' record revenue was overshadowed by a 10% data center miss and rising debt, making the stock a watchlist candidate until execution improves.
TTMIOct 23, 2026